BMS CCR2 22High affinity, potent CCR2 antagonist CAS# 445479-97-0 |
- BMS-708163 (Avagacestat)
Catalog No.:BCC2104
CAS No.:1146699-66-2
- Compound W
Catalog No.:BCC2341
CAS No.:173550-33-9
- DAPT (GSI-IX)
Catalog No.:BCC3618
CAS No.:208255-80-5
- Semagacestat (LY450139)
Catalog No.:BCC3610
CAS No.:425386-60-3
- MK-0752
Catalog No.:BCC2090
CAS No.:471905-41-6
- Begacestat
Catalog No.:BCC2346
CAS No.:769169-27-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 445479-97-0 | SDF | Download SDF |
PubChem ID | 57350027 | Appearance | Powder |
Formula | C28H34F3N5O4S | M.Wt | 593.66 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 10 mM in ethanol | ||
Chemical Name | N-[2-[[(1R,2S)-2-[(4-methylsulfanylbenzoyl)amino]cyclohexyl]amino]-2-oxoethyl]-2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzamide | ||
SMILES | CC(C)NC(=O)NC1=C(C=C(C=C1)C(F)(F)F)C(=O)NCC(=O)NC2CCCCC2NC(=O)C3=CC=C(C=C3)SC | ||
Standard InChIKey | IBPXYDUJQWENPM-PKTZIBPZSA-N | ||
Standard InChI | InChI=1S/C28H34F3N5O4S/c1-16(2)33-27(40)36-21-13-10-18(28(29,30)31)14-20(21)26(39)32-15-24(37)34-22-6-4-5-7-23(22)35-25(38)17-8-11-19(41-3)12-9-17/h8-14,16,22-23H,4-7,15H2,1-3H3,(H,32,39)(H,34,37)(H,35,38)(H2,33,36,40)/t22-,23+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | High affinity CCR2 chemokine receptor antagonist (IC50 = 5.1 nM). Displays potent functional antagonism, IC50 values are 1 and 18 nM for chemotaxis and antagonism of calcium flux respectively. Selective over CCR3. |
BMS CCR2 22 Dilution Calculator
BMS CCR2 22 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6845 mL | 8.4223 mL | 16.8447 mL | 33.6893 mL | 42.1116 mL |
5 mM | 0.3369 mL | 1.6845 mL | 3.3689 mL | 6.7379 mL | 8.4223 mL |
10 mM | 0.1684 mL | 0.8422 mL | 1.6845 mL | 3.3689 mL | 4.2112 mL |
50 mM | 0.0337 mL | 0.1684 mL | 0.3369 mL | 0.6738 mL | 0.8422 mL |
100 mM | 0.0168 mL | 0.0842 mL | 0.1684 mL | 0.3369 mL | 0.4211 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SGS 518 oxalate
Catalog No.:BCC7750
CAS No.:445441-27-0
- BMS-345541(free base)
Catalog No.:BCC5374
CAS No.:445430-58-0
- ZM 449829
Catalog No.:BCC2444
CAS No.:4452-06-6
- 1,4:3,6-Dianhydro-α-D-glucopyranose
Catalog No.:BCC8420
CAS No.:4451-30-3
- EBPC
Catalog No.:BCC6677
CAS No.:4450-98-0
- TC-O 9311
Catalog No.:BCC7900
CAS No.:444932-31-4
- AM1241
Catalog No.:BCC2551
CAS No.:444912-48-5
- Warangalone
Catalog No.:BCN4788
CAS No.:4449-55-2
- Cyclopamine
Catalog No.:BCN2964
CAS No.:4449-51-8
- CMX001
Catalog No.:BCC4106
CAS No.:444805-28-1
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- Norwogonin
Catalog No.:BCN3190
CAS No.:4443-09-8
- Homoeriodictyol
Catalog No.:BCN6804
CAS No.:446-71-9
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
- Azathioprine
Catalog No.:BCC4762
CAS No.:446-86-6
- 2,4,5-Trimethoxybenzaldehyde
Catalog No.:BCN5498
CAS No.:4460-86-0
- YM 230888
Catalog No.:BCC5956
CAS No.:446257-23-4
- 4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one
Catalog No.:BCC8646
CAS No.:446292-10-0
- RepSox
Catalog No.:BCC1887
CAS No.:446859-33-2
- Angiotensin II human
Catalog No.:BCC4087
CAS No.:4474-91-3
- RLLFT-NH2
Catalog No.:BCC3954
CAS No.:447408-68-6
- Ruixianglangdusu B
Catalog No.:BCN6869
CAS No.:447454-49-1
- Sulforaphane
Catalog No.:BCN2349
CAS No.:4478-93-7
- Betulonic acid
Catalog No.:BCN5500
CAS No.:4481-62-3
High-content analysis of CCR2 antagonists on human primary monocytes.[Pubmed:21540351]
J Biomol Screen. 2011 Aug;16(7):683-93.
The monocyte chemoattractant protein 1 (MCP-1)-driven activation of CC-type chemokine receptor 2 (CCR2) is one of the early key events to induce monocyte migration toward centers of inflammation. In this work, the authors analyzed MCP-1 internalization into primary human monocytes using partially automated liquid handling, automated fluorescence microscopic imaging, and a specific image analysis algorithm. A fluorophore-conjugated form of MCP-1 was rapidly endocytosed and retained by the monocytes. The CCR2 dependency of the MCP-1 internalization was demonstrated by the use of BMS CCR2 22, a CCR2-specific antagonist. The apparent inhibitory potencies of a series of small-molecule CCR2 antagonists were determined and compared in five assay formats, including the high-content analysis assay described in this work. Interestingly, some but not all antagonists showed markedly different inhibitory behaviors in the five readout systems, with an up to more than 100-fold difference between the highest and the lowest apparent inhibitory potencies. These findings raise the distinct possibility that some CCR2 antagonists are capable of discriminating between different functional states of the CCR2 receptor(s) and suggest strategies for the identification of functionally selective CCR2 antagonists with increased therapeutic advantage over nonselective antagonists.
CCR2 receptor ligands inhibit Cav3.2 T-type calcium channels.[Pubmed:19864434]
Mol Pharmacol. 2010 Feb;77(2):211-7.
Monocyte chemoattractant protein-1 (MCP-1) is a cytokine known to be involved in the recruitment of monocytes to sites of injury. MCP-1 activates the chemokine (C-C motif) receptor 2 (CCR2), a seven-transmembrane helix G protein-coupled receptor that has been implicated in inflammatory pain responses. Here we show that MCP-1 mediates activation of the CCR2 receptor and inhibits coexpressed N-type calcium channels in tsA-201 cells via a voltage-dependent pathway. Moreover, MCP-1 inhibits Ca(v)3.2 calcium channels, but not other members of the Cav3 calcium channel family, with nanomolar affinity. Unlike in N-type channels, this modulation does not require CCR2 receptor activation and seems to involve a direct action of the ligand on the channel. Whole-cell T-type calcium currents in acutely dissociated dorsal root ganglia neurons are effectively inhibited by MCP-1, consistent with the notion that these cells express Ca(v)3.2. The effects of MCP-1 were eliminated by heat denaturation. Furthermore, they were sensitive to the application of the divalent metal ion chelator diethylenetriaminepentaacetic acid, suggesting the possibility that metal ions may act as a cofactor. Finally, small organic CCR2 receptor antagonists inhibit Ca(v)3.2 and other members of the T-type channel family with micromolar affinity. Our findings provide novel avenues for the design of small organic inhibitors of T-type calcium channels for the treatment of pain and other T-type channel linked disorders.
Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists.[Pubmed:18232650]
J Med Chem. 2008 Feb 28;51(4):721-4.
We describe the design, synthesis, and evaluation of novel disubstituted cyclohexanes as potent CCR2 antagonists. Exploratory SAR studies led to the cis-disubstituted derivative 22, which displayed excellent binding affinity for CCR2 (binding IC50 = 5.1 nM) and potent functional antagonism (calcium flux IC50 = 18 nM and chemotaxis IC 50 = 1 nM). Site-directed mutagenesis studies with 22 suggest the compound is binding near the key receptor residue Glu291, however, 22 is not reliant on Glu291 for its binding affinity.